Pipeline

Our aim is to develop the right antibody for the right target, ultimately producing a treatment that is safer and more effective for patients with Alzheimer’s disease.

The first of its kind to enter the clinic, sabirnetug, an immunotherapy drug candidate, is designed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, sabirnetug addresses an underlying cause of 
Alzheimer’s disease by preventing toxic AβOs from binding to dendritic spines and helping
preserve neuronal function.

Sabirnetug (ACU193) Formulation Indication Discovery / Preclinical Research Clinical Research
Phase 1 Phase 2 Phase 3
Intravenous (IV) Infusion Early Alzheimer’s disease
INTERCEPT-AD
ALTITUDE-AD
Subcutaneous (SC) Early Alzheimer’s disease

ALTITUDE-AD

NCT identifier NCT06335173

This actively enrolling study is a Phase 2, global, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenous sabirnetug (ACU193) in early Alzheimer’s disease.

LEARN MORE

INTERCEPT-AD

NCT identifier NCT04931459

This completed study was a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and tolerability, and to establish the clinical proof of mechanism, of sabirnetug (ACU193) in early Alzheimer’s disease.

LEARN MORE